Lilly says lab tests found bacteria and impurities in knockoff tirzepatide

Eli Lilly said on March 7, 2024 that it has found bacteria and high levels of impurities in products sold as compounded versions of tirzepatide, the active ingredient in its diabetes drug Mounjaro and its weight-loss drug Zepbound ^[1]. The company laid out the findings in an updated open letter and said it will keep taking legal action against sellers, including certain medical spas, wellness centers and compounding pharmacies ^[2].

Beyond contamination, Lilly said some of the products it examined had "different chemical structures" and a different color than approved Mounjaro or Zepbound ^[1][2]. "In at least one instance, the product was nothing more than sugar alcohol," the company said ^[1]. Lilly also repeated a point it has made before: it does not sell anything called simply "tirzepatide," and it does not supply the ingredient to any compounding pharmacy ^[1][2].

The letter was a republished version of one Lilly issued in January that objected to off-label use of its GLP-1 drugs for cosmetic weight loss ^[2]. The legal push predates it. Last fall, Lilly filed eight complaints seeking unspecified damages across five states, targeting four compounding pharmacies and four medical spas and wellness centers — one of which was advertising Mounjaro on its website even though Lilly does not supply the branded drug to such sellers. That med spa has since removed the product from its site ^[2]. Lilly has sued several medical spas, weight-loss clinics and compounding pharmacies to stop them from selling products claiming to contain tirzepatide ^[1].

The compounding industry pushes back

The trade group representing compounding pharmacists disputed the framing. "Lilly rightly notes that compounded drugs are not FDA-approved. But that fact does not mean compounded drugs are unsafe – any more than it means that FDA-approved drugs are always safe," said Scott Brunner, CEO of the Alliance for Pharmacy Compounding ^[1]. Brunner also said it was not clear whether the products Lilly tested came from a state-licensed pharmacy at all. Licensed pharmacies can legally produce compounded drugs when the branded version is in shortage; if the products came from somewhere else, Brunner argued, they would not be compounded drugs in the first place ^[1].

That distinction matters and the sources do not resolve it. Lilly's letter describes both "fake and compounded" versions together ^[2], and the reporting does not say how many samples were tested, where each one was bought, or which findings came from licensed pharmacies versus unregulated online sellers. Those details are not yet known from the available sources.

Lilly is not alone. Novo Nordisk, which makes semaglutide (Ozempic, Wegovy, Rybelsus), has taken similar legal action against sellers of products claiming to contain semaglutide ^[1]. In December, Novo reported that some samples of compounded semaglutide were up to 33% impure ^[1]. Separately, the American Association of Poison Control Centers told Reuters in January that unauthorized Ozempic copycats sent three people to the hospital last year with hypoglycemia, or dangerously low blood sugar ^[2].

Why it matters for patients

Compounded drugs are custom-made medicines based on the same ingredients as branded versions, are often cheaper, and are subject to less regulatory scrutiny ^[1]. For people facing high out-of-pocket costs or spotty supply, that price gap is the main draw — and it is also where the risk sits.

The specific problems Lilly described are the kind a patient cannot detect at home: bacterial contamination, impurity levels, and molecules that are not tirzepatide at all ^[1][2]. A vial labeled "tirzepatide" carries no guarantee about what is inside it, and Lilly's statement that it never supplies the ingredient to compounders means no product sold that way traces back to the brand manufacturer ^[1][2].

It is also worth reading the source of these claims carefully. The findings come from the company that sells the branded product and is suing the sellers, and the compounding trade group has contested the characterization ^[1]. The sources do not include an independent regulator's testing of the same samples.

What happens next

Lilly said it will continue pursuing legal action against sellers of the fraudulent products ^[2]. The eight complaints filed last fall across five states are seeking unspecified damages ^[2]. No court dates, settlement terms or regulatory actions tied to these test findings are described in the available sources.